Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13525147 | 0.84 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13525150 | 0.81 | CA12 (0.56) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13546030 | 0.79 | CA12 (0.42) | CA12CA1CA2CA4CA9 | |
| SCHEMBL22227473 | 0.78 | CA2 (0.48) | CA12CA1CA2CA4CA9 | |
| SCHEMBL15928851 | 0.76 | CA12 (0.40) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7278868 | 0.76 | CES1 (0.57) | CA12CA1ALDH1A1FNTAFNTB | |
| SCHEMBL220304 | 0.76 | CA2 (0.53) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13685904 | 0.74 | CA12 (0.48) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3306193 | 0.74 | ALDH1A1 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13525145 | 0.74 | TMEM97 (0.44) | TMEM97ALDH1A1MAPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645748-B2 | include a phosphate linker, at least one nitrate group that releases nitric oxide (NO), and a sterol or stanol group; useful for treating atherosclerosis, hypercholesterolemia, hyperlipidemia, hypertension, thrombosis, Type II diabetes, dementia, Alzheimer's disease and aging | FORBES MEDI-TECH INC. (CA) | 2010-01-12 | — | — | US | disclosed |
| US-7645749-B2 | contains ester linkage of a nitric oxide (NO)-releasing moiety to a sterol or stanol compound; useful for treating atherosclerosis, hypercholesterolemia, hyperlipidemia, hypertension, thrombosis, Type II diabetes, dementia, Alzheimer's disease and aging | FORBES MEDI-TECH INC. (CA) | 2010-01-12 | — | — | US | disclosed |
| US-20070232580-A1 | Novel sterol/stanol nitroderivatives and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders | FORBES MEDI-TECH INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232688-A1 | Novel sterol/stanol phosphorylnitroderivatives and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders | FORBES MEDI-TECH INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232688-A1 | Novel sterol/stanol phosphorylnitroderivatives and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders | CYP27A1, CYP27B1, HSD11B1 | CA12 4681/4885CA1 4694/4885CA2 3889/4885 |
| US-20070232580-A1 | Novel sterol/stanol nitroderivatives and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders | CYP27A1, HSD11B1, NOS1 | CA12 4650/4885CA1 4811/4885CA2 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.